At a glance
Effects
- Endurance / exercise mimicry: In mice, REV-ERB activation increased mitochondrial content in skeletal muscle and significantly improved running time and distance [4][7].
- Fat oxidation: Promotes fatty-acid burning for energy and suppresses hepatic gluconeogenesis, potentially reducing fat storage [2][5].
- Glucose / insulin metabolism: Chronic SR9009 treatment induced glycolytic enzyme expression in muscle and reduced plasma glucose in rodent models [6].
- Circadian-rhythm modulation: REV-ERB agonism modulates the body's internal clock; animal studies suggest influence on sleep architecture and activity rhythms [7].
- Anti-inflammatory signalling: Preclinical evidence shows SR9009 inhibited inflammatory pathways (NF-κB, Gab2/PI3K) in mast-cell and colitis models [8].
Rev-ErbA agonist (circadian / metabolic modulator — NOT a SARM, NOT a steroid)
~2–4 hours (estimated; no human PK data)
Oral (very poor bioavailability ~2–3% in rodents); sublingual liquid used by some; injectable routes exist but uncharacterised
None — research chemical only; not FDA-approved, not EMA-approved
Prohibited — Banned List (all sports, in and out of competition)
About Stenabolic
Every point here is drawn from public medical and harm-reduction sources. A bracketed number after a claim — like [1]— is a reference: tap it to open the exact source it's based on (numbered list at the bottom). It is not a rating or score. Educational information, not medical advice.
Product specifics
- Est. delivery
- 3–7 business days · EU tracked
Product details as stated by the vendor (claims, not independently verified). Delivery is our standard EU estimate.
What it is
Stenabolic (SR9009) is a synthetic Rev-ErbA agonist — a circadian-clock and metabolic modulator — developed at the Scripps Research Institute as a research tool compound [1]. It is not a SARM, not a hormone, and has never been approved for human use; all supporting efficacy data come from preclinical (rodent) studies only [2][3].
How it works
SR9009 binds and activates the nuclear receptors REV-ERBα and REV-ERBβ, transcriptional repressors that regulate circadian-clock gene networks governing metabolism, inflammation, and mitochondrial turnover [4][7]. By driving REV-ERB activity, the compound promotes fatty-acid oxidation, suppresses hepatic glucose production, and — in animal models — triggers mitochondrial biogenesis in skeletal muscle, producing an "exercise-mimetic" effect [2][5]. Critically, several published phenotypes have been shown to be REV-ERB-independent, meaning the molecule also operates through unidentified off-target pathways [1][3].
Risks & side effects
Most important: SR9009 has never been studied in human clinical trials — there is no human pharmacokinetic data, no human safety data, and no established safe dose for any route of administration [3]. Because its off-target pathways are unknown, the nature and severity of adverse effects in humans remain entirely undetermined [1].
Common
Serious
- Unknown cardiovascular consequences — animal models show complex cardiac remodelling effects; human translation is undetermined [4]
- Circadian-rhythm disruption — mechanistic off-target clock effects could impair sleep, hormonal regulation, and immune timing [7]
- Completely unknown long-term toxicity profile — no chronic human exposure data of any kind exist [3]
- Poor oral bioavailability (~2–3% in mice) leading users to explore injectable or sublingual routes with additional safety unknowns [10]
Safety & harm reduction
- Anyone under 18 — compound has never been evaluated in any human population [2]
- Pregnant or breastfeeding individuals — no safety data whatsoever [3]
- Competitive athletes subject to WADA, USADA, or national anti-doping authority testing — SR9009 is a prohibited substance [11]
- Individuals with known cardiovascular, hepatic, or metabolic disease — off-target effects are undefined [3]
- Anyone seeking an approved medicinal product — SR9009 is not one [2]
- Lipid panel and fasting glucose (REV-ERB targets lipid/glucose pathways; baseline and periodic monitoring prudent) [5]
- Liver function tests (LFTs) — off-target hepatic effects unknown in humans [3]
- Cardiovascular markers (resting HR, blood pressure) given mechanistic cardiac effects in animal models [4]
- Sleep quality and circadian-rhythm disturbance — self-monitor insomnia or worsening sleep patterns [9]
- Other circadian-clock modulators (e.g. melatonin, ramelteon) — additive or opposing clock effects unpredictable [7]
- Glucose-lowering agents (insulin, metformin, GLP-1 agonists) — mechanistic glucose lowering may potentiate hypoglycaemia [5]
- Lipid-modifying drugs (statins, fibrates) — additive lipid-pathway effects possible; interaction data absent [5]
- PPARδ agonists (e.g. GW501516/Cardarine) — commonly stacked; combined metabolic and off-target risks are entirely uncharacterised [1]
- No PCT required — SR9009 does not suppress the hypothalamic-pituitary-gonadal axis or androgenic hormones [1]
- No liver-support supplement protocol is validated — but given unknown hepatic off-target effects, conservative users may consider TUDCA/NAC monitoring approach [3]
- Due to very short half-life, users commonly split any dose into 3–4 sub-doses throughout the day to maintain nominal plasma levels [12]
- Sublingual liquid administration is reported to improve absorption over standard oral capsules, though human bioavailability data remain absent [10]
Dosage context
No human dose has been clinically established. All preclinical work used intraperitoneal injection at ~100 mg/kg in mice — a route and scale that does not translate to human oral dosing [9]. Community-reported oral doses range from 10–40 mg/day split into 3–4 administrations every 4–6 hours, reflecting the short estimated half-life [12][9]. These are anecdotal figures with no safety validation; they are reported here for harm-reduction context only and must not be interpreted as recommended or safe doses [3].
Sources
- 1.Wikipedia — SR9009
- 2.MedXDrg — Stenabolic pharmacological & safety overview
- 3.PeptideInsight — SR9009 Research Evidence & Safety Profile
- 4.RCPeptides — SR9009 compound overview (link unavailable)
- 5.Anabolic Planner — Stenabolic SR9009 compound profile
- 6.PMC — REV-ERBα agonist SR9009 in goldfish (energy balance)
- 7.PMC — SR9009 effects on circadian clock / mast cell activation
- 8.PNAS — SR9009 REV-ERB–independent effects on proliferation & metabolism
- 9.SelfDecode / SelfHacked — SR9009 effects & dosage
- 10.Sarms.io — SR9009 bioavailability: oral vs injection
- 11.HealthEd Academy — SR9009 review 2026
- 12.Muscle and Brawn — Stenabolic SR9009 dosage & results
This information is provided for educational and harm-reduction purposes only. It is not medical advice. These substances can carry serious health risks; effects and safe use vary by individual. Consult a qualified healthcare professional before use. Legal status varies by country — it is your responsibility to know your local law. We do not encourage misuse.
Other options for Stenabolic· 3 offers
Same compound from different labs/brands and pack sizes. Tap a row to switch brand — the price and buy button update instantly.
This compound comes in different forms (e.g. injectable vs oral vs topical). Cost per mg is only comparable within the same form.
| Brand | Form | Strength | Pack | Price | Per mg |
|---|---|---|---|---|---|
Generic | blister-pack | 10 mg/tab | 30 tab | 89,90 € | €0.300/mg |
GenericSelected | bottle | 20 mg/ml | 50 ml | 104,99 € | €0.105/mg |
Generic | bottle | 20 mg/ml | 100 ml | 199,99 € | ★€0.100/mg |